We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
Read MoreHide Full Article
Key Takeaways
CVS stock is up nearly 50% YTD, driven by strong Q1 results and rising investor confidence.
The Senate dropped PBM and Medicare cuts, lifting a key overhang for CVS's Caremark and Aetna units.
CVS raised 2025 EPS guidance to $6.00-$6.20 after segment-wide growth and operational efficiency.
CVS Health Corporation (CVS - Free Report) is gaining investor attention as the stock trends higher ahead of its second-quarter earnings release, scheduled for July 30, 2025. A key catalyst behind the recent uptick occurred in mid-June, when Bloomberg reported that proposed Medicare Pharmacy Benefit Manager (PBM) limits were stripped from the Senate’s version of the tax bill, removing a major overhang for CVS Health and other healthcare insurers.
As one of the nation’s largest PBM operators through its Caremark division, CVS stands to benefit from reduced regulatory pressure, alongside peers like Cigna (CI - Free Report) and UnitedHealth (UNH - Free Report) . Combined with strong first-quarter earnings, upgraded full-year guidance and operational momentum across its healthcare segments, CVS is entering the second-quarter earnings season with growing market confidence. Here's a closer look at the drivers behind the stock’s recent rise.
Turnaround After 2024 Headwinds
CVS Health has staged a notable turnaround in 2025 after navigating significant challenges in recent years, including the closure of approximately 900 stores between 2022 and 2024 and utilization-related pressure within its Aetna health insurance segment. These headwinds had weighed heavily on the stock, but it has recovered much of the lost ground so far in 2025. CVS shares have rallied nearly 50% year to date, banking on strong strategic execution in the first quarter of 2025 and improved operational efficiency.
During this period, archrivals like Cigna grew 10.9% while United Health shares dipped 39.2%.
YTD Price Performance
Image Source: Zacks Investment Research
Strong Q1 Performance, Segment Growth and Upgraded 2025 Guidance
CVS Health delivered strong first-quarter 2025 results in May, reporting a 7% year-over-year revenue increase and a sharp jump in adjusted EPS to $2.25 from $1.31 a year earlier. The company also raised its full-year adjusted EPS guidance to a range of $6.00–$6.20 (up from $5.75–$6.00) and now expects around $7 billion in cash flow.
Growth was broad-based across CVS’ three business segments, Health Care Benefits, Health Services and Pharmacy & Consumer Wellness, which grew 8%, 7.9%, and 11.1%, respectively, in the first quarter. Aetna, its insurance unit, benefited from higher Medicare Advantage star ratings and favorable prior-year cost adjustments, reinforcing the company’s earnings momentum and operational efficiency.
The Zacks Consensus Estimate for CVS’ 2025 earnings per share suggests a 12.9% improvement from 2024.
Image Source: Zacks Investment Research
CVS to Benefit From Senate's Removal of PBM and Medicare Advantage Cuts
As stated earlier, CVS Health is gaining from the Senate’s decision to drop proposed limits on PBMs and cuts to Medicare Advantage in the latest tax bill. This removes a key regulatory risk for its Caremark PBM unit. The decision also boosts Aetna’s Medicare Advantage business by preserving federal funding, supporting stable revenues and continued investment in member services like in-home care.
Additionally, CVS is enhancing care delivery by processing 95% of prior authorizations within 24 hours and expanding value-based care into oncology and cardiology. Its pharmacy unit, which fills over 1.7 billion prescriptions annually, leads in adherence and affordability, driven by initiatives such as low-cost access to Wegovy and Cordavis, delivering over $1 billion in client savings.
CVS Health Offers Attractive Valuation
In terms of valuation, CVS Health’s forward 12-month price-to-earnings (P/E) is 9.83X, a discount to the S&P 500’s 22.63X.
Image Source: Zacks Investment Research
The stock is trading at a premium to the company’s competitor Cigna’s P/E of 9.63X. However, it is trading at a discount to United Health’s 12.85X.
CVS stock’s premium over CI may be justified by its scale, efficiency and strategic focus on digital health, AI and value-based care. Meanwhile, its discount to the S&P 500 offers an attractive entry point for long-term investors seeking stable, growth-oriented healthcare exposure.
Buy CVS Health Now
With strong operational momentum, easing regulatory headwinds and an attractive valuation, CVS Health stands out as a solid buy ahead of its second-quarter earnings. A near 50% YTD rally reflects renewed investor confidence driven by robust first-quarter results, raised guidance and continued strength across business segments. The Senate’s removal of PBM and Medicare Advantage cuts further boosts the outlook for its Caremark and Aetna units. While Cigna has seen modest gains and UnitedHealth faces sharp declines, CVS offers a stronger growth profile, enhanced by its focus on value-based care and digital health. Carrying a Zacks Rank #2 (Buy), CVS presents an appealing opportunity for investors seeking stable, growth-oriented healthcare exposure. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
Key Takeaways
CVS Health Corporation (CVS - Free Report) is gaining investor attention as the stock trends higher ahead of its second-quarter earnings release, scheduled for July 30, 2025. A key catalyst behind the recent uptick occurred in mid-June, when Bloomberg reported that proposed Medicare Pharmacy Benefit Manager (PBM) limits were stripped from the Senate’s version of the tax bill, removing a major overhang for CVS Health and other healthcare insurers.
As one of the nation’s largest PBM operators through its Caremark division, CVS stands to benefit from reduced regulatory pressure, alongside peers like Cigna (CI - Free Report) and UnitedHealth (UNH - Free Report) . Combined with strong first-quarter earnings, upgraded full-year guidance and operational momentum across its healthcare segments, CVS is entering the second-quarter earnings season with growing market confidence. Here's a closer look at the drivers behind the stock’s recent rise.
Turnaround After 2024 Headwinds
CVS Health has staged a notable turnaround in 2025 after navigating significant challenges in recent years, including the closure of approximately 900 stores between 2022 and 2024 and utilization-related pressure within its Aetna health insurance segment. These headwinds had weighed heavily on the stock, but it has recovered much of the lost ground so far in 2025. CVS shares have rallied nearly 50% year to date, banking on strong strategic execution in the first quarter of 2025 and improved operational efficiency.
During this period, archrivals like Cigna grew 10.9% while United Health shares dipped 39.2%.
YTD Price Performance
Image Source: Zacks Investment Research
Strong Q1 Performance, Segment Growth and Upgraded 2025 Guidance
CVS Health delivered strong first-quarter 2025 results in May, reporting a 7% year-over-year revenue increase and a sharp jump in adjusted EPS to $2.25 from $1.31 a year earlier. The company also raised its full-year adjusted EPS guidance to a range of $6.00–$6.20 (up from $5.75–$6.00) and now expects around $7 billion in cash flow.
Growth was broad-based across CVS’ three business segments, Health Care Benefits, Health Services and Pharmacy & Consumer Wellness, which grew 8%, 7.9%, and 11.1%, respectively, in the first quarter. Aetna, its insurance unit, benefited from higher Medicare Advantage star ratings and favorable prior-year cost adjustments, reinforcing the company’s earnings momentum and operational efficiency.
The Zacks Consensus Estimate for CVS’ 2025 earnings per share suggests a 12.9% improvement from 2024.
Image Source: Zacks Investment Research
CVS to Benefit From Senate's Removal of PBM and Medicare Advantage Cuts
As stated earlier, CVS Health is gaining from the Senate’s decision to drop proposed limits on PBMs and cuts to Medicare Advantage in the latest tax bill. This removes a key regulatory risk for its Caremark PBM unit. The decision also boosts Aetna’s Medicare Advantage business by preserving federal funding, supporting stable revenues and continued investment in member services like in-home care.
Additionally, CVS is enhancing care delivery by processing 95% of prior authorizations within 24 hours and expanding value-based care into oncology and cardiology. Its pharmacy unit, which fills over 1.7 billion prescriptions annually, leads in adherence and affordability, driven by initiatives such as low-cost access to Wegovy and Cordavis, delivering over $1 billion in client savings.
CVS Health Offers Attractive Valuation
In terms of valuation, CVS Health’s forward 12-month price-to-earnings (P/E) is 9.83X, a discount to the S&P 500’s 22.63X.
Image Source: Zacks Investment Research
The stock is trading at a premium to the company’s competitor Cigna’s P/E of 9.63X. However, it is trading at a discount to United Health’s 12.85X.
CVS stock’s premium over CI may be justified by its scale, efficiency and strategic focus on digital health, AI and value-based care. Meanwhile, its discount to the S&P 500 offers an attractive entry point for long-term investors seeking stable, growth-oriented healthcare exposure.
Buy CVS Health Now
With strong operational momentum, easing regulatory headwinds and an attractive valuation, CVS Health stands out as a solid buy ahead of its second-quarter earnings. A near 50% YTD rally reflects renewed investor confidence driven by robust first-quarter results, raised guidance and continued strength across business segments. The Senate’s removal of PBM and Medicare Advantage cuts further boosts the outlook for its Caremark and Aetna units. While Cigna has seen modest gains and UnitedHealth faces sharp declines, CVS offers a stronger growth profile, enhanced by its focus on value-based care and digital health. Carrying a Zacks Rank #2 (Buy), CVS presents an appealing opportunity for investors seeking stable, growth-oriented healthcare exposure. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.